These and other outcomes for effectiveness of BTX-A at different dosages in two observation periods indicate that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo .
However , there were no significant differences between some dosages .
Compared with placebo , the outcomes of total adverse events for NDO and for IDO show that doses of 300 U and 200 U for NDO are associated with more complications .
Conclusions In consideration that the treatments of BTX-A were with minimal , local , and manageable adverse effects , this meta- analysis demonstrates that BTX-A 200 U is recommended for management of NDO for short-term treatment for there was no significant difference from the larger dose of 300U .
Purpose To assess the effectiveness and safety of botulinum toxin A ( BTX-A ) at different dosages for overactive bladder ( OAB ) .
Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
OBJECTIVES To investigate the clinical and urodynamic effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity . Intradetrusor injection of botulinum A toxin has been used to treat patients with detrusor overactivity .  Suburothelial injection of botulinum A toxin might effectively inhibit the occurrence of detrusor overactivity mediated by sensory nerves . METHODS Twenty patients with nonneurogenic detrusor overactivity refractory to anticholinergics were enrolled and treated with injection of 200 U botulinum A toxin into the suburothelial space . The clinical effects on the lower urinary tract symptoms and urodynamic parameters were assessed . RESULTS At 3 months after treatment , 9 patients had regained continence ( 45 % ) , 8 had improvement ( 40 % ) , and treatment had failed in 3 ( 15 % ) . At 6 months after treatment , 7 patients remained continent , but treatment had failed in 5 . Hematuria developed in 1 patient , urinary tract infection in 7 ( 35 % ) , and a large postvoid residual urine volume requiring catheterization in 6 ( 30 % ) . Hesitancy in initiation and difficult urination was also noted in 15 patients ( 75 % ) . The volume of the first sensation of bladder filling and bladder capacity increased about two times ; however , the voiding efficiency was reduced by 50 % at 2 weeks after treatment . The postvoid residual urine volume was increased by seven times the baseline value at 2 weeks and had decreased to three times greater at 3 and 6 months after treatment . CONCLUSIONS The results of this study have shown that suburothelial injection of 200 U botulinum A toxin impairs bladder sensation and voiding efficiency , but is effective in the treatment of nonneurogenic detrusor overactivity . Transient urinary retention and the development of urinary tract infection should be carefully monitored
These and other outcomes for effectiveness of BTX-A at different dosages in two observation periods indicate that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo .
However , there were no significant differences between some dosages .
Compared with placebo , the outcomes of total adverse events for NDO and for IDO show that doses of 300 U and 200 U for NDO are associated with more complications .
Conclusions In consideration that the treatments of BTX-A were with minimal , local , and manageable adverse effects , this meta- analysis demonstrates that BTX-A 200 U is recommended for management of NDO for short-term treatment for there was no significant difference from the larger dose of 300U .
Purpose To assess the effectiveness and safety of botulinum toxin A ( BTX-A ) at different dosages for overactive bladder ( OAB ) .